エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-42453
Park Ha Biological Technology Co., Ltd.
901 & 901-2, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Information Contained in this Form 6-K Report
Announces Official Approval of North American Amazon Store
On July 6, 2026, Park Ha Biological Technology Co., Ltd. (the “Registrant”) announced that it has successfully passed the comprehensive and rigorous process to open a store on Amazon North America. The cross-border store has been officially approved for opening, and all registration procedures are complete. This successful entry represents a critical milestone in the execution of the Registrant’s global expansion strategy, reflecting the Amazon platform’s authoritative recognition of the Registrant’s overall brand strength, core product competitiveness, and standardized operational excellence.
Amazon enforces exceptionally high standards and rigorous evaluation criteria for its onboarding process, selecting only premium enterprises with strong brand qualifications and compliance. By successfully passing this review, the Registrant has demonstrated its distinct core advantages, allowing it to stand out in a highly competitive market.
This successful launch marks the Registrant’s strategic evolution into an emerging international brand, unlocking key access channels to the global high-end consumer market. Moving forward, the Registrant will utilize Amazon as its primary international launching pad, leveraging the platform’s traffic, FBA logistics, and big data to refine its product offerings for North America, enhance brand exposure, and establish itself as a globally influential benchmark brand.
The foregoing description is qualified in its entirety by the press release attached as Exhibit 99.1 to this Form 6-K.
Issuance of Press Release
On July 6, 2026, the Registrant issued a press release announcing the event described above. A copy of the press release is attached hereto as Exhibit 99.1.
Forward Looking Statements
Matters discussed in this report may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are not historical facts. Words such as “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions identify forward-looking statements. The forward-looking statements in this report are based upon various assumptions. Although the Registrant believes that these assumptions were reasonable when made, they are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Registrant’s control, the Registrant cannot assure you that it will achieve or accomplish these expectations. Actual results may differ materially from those anticipated. The Registrant undertakes no obligation to update or revise any forward-looking statements, except as required by law.
1
EXHIBIT INDEX
The following exhibit is being filed herewith:
| Exhibit No. | Description | |
| 99.1 | Press release of the Company dated July 6, 2026 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Park Ha Biological Technology Co., Ltd. | ||
| Date: July 6, 2026 | By: | /s/ Xiaoqiu Zhang |
| Name: | Xiaoqiu Zhang | |
| Title: | Chief Executive Officer, Chairperson of the Board of Directors | |
3
Exhibit 99.1
Park Ha Biological Technology Co., Ltd. Announces Official Approval of Its North American Amazon Store, Launching a New Era of Brand Globalization
Wuxi, China, July 06, 2026 (GLOBE NEWSWIRE) --Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (“Park Ha Biological” or the “Company”) announced that it has successfully passed the comprehensive and rigorous process to open a store on Amazon North America, and the cross-border store has been officially approved for opening and all registration procedures have been completed. This successful entry represents a critical milestone in the execution of the Company’s global expansion strategy, reflecting the Amazon platform’s authoritative recognition of Park Ha Biological’s overall brand strength, core product competitiveness, and standardized operational excellence.
As the world’s leading cross-border e-commerce platform, Amazon has consistently maintained strict onboarding mechanisms with exceptionally high standards. It enforces rigorous evaluation criteria regarding brand qualifications, compliant operational frameworks, and market reputation, selecting only premium enterprises that possess core competitiveness and long-term brand-building capabilities. As such, it serves as a premier benchmark for curating high-quality brands within the global high-end consumer market. By successfully passing this multi-dimensional evaluation and securing its approval, Park Ha Biological has leveraged its differentiated core advantages to stand out in a highly commoditized market.
The successful launch on Amazon marks the formal completion of Park Ha Biological’s strategic evoluation from a “premium domestic brand” to an “emerging international brand”, fully unlocking key access channels to the global high-end consumer market.Moving forward, the Company will utilize Amazon’s store as its primary international launching pad, fully capitalizing on the platform’s global traffic, Fulfillment by Amazon (FBA) overseas logistics, brand empowerment tools, and big data resources to continuously amplify its competitive edge. On one hand, the Company will precisely iterate its product portfolio tailored to the consumption habits of core North American markets, delivering high-quality, highly adaptable, and cost-effective premium Chinese products; On the other hand, the Company will focus on refined cross-bordered brand operations to continuous enhance international brand exposure and consumer mindshare. This approach moves away from the traditional, product-only output mode of conventional foreign trade, achieving a comprehensive upgrade across technology, quality, and brand equity
With this new global starting point, Park Ha Biological will stay true to its original vision by focusing on product innovation and quality upgrades. By leveraging Amazon’s ecosystem, the Company aims to explore global market potential, compete internationally through its brand strength, and work toward becoming a benchmark domestic brand with global influence—helping more high-quality Chinese brands succeed on the global stage.
About Park Ha Biological Technology Co., Ltd.
Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare product sales and franchise promotion under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of October 31, 2025, the Company has five directly operated stores and 22 franchisees in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects, “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.
For more information, please contact:
Park Ha Biological
Technology Co., Ltd.
901 & 901-2, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
ir_parkha@163.com